FDA Approves Trodelvy — A Breakthrough Treatment For One Of The Deadliest Breast Cancers
The FDA's approval of Trodelvy, a targeted treatment, could bring new hope for Black women battling metastatic triple-negative breast cancer. The post FDA Approves Trodelvy — A Breakthrough Treatment For One Of The Deadliest Breast Cancers appeared first on MadameNoire.
Black News 
A groundbreaking new treatment is giving fresh hope to people diagnosed with one of the most aggressive forms of breast cancer. The U.S. Food and Drug Administration (FDA) has approved Trodelvy, a chemotherapy medicine that can now be used as a first-line treatment for adults with unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC). The milestone marks a major advancement for patients facing a disease that has long had limited treatment options, particularly Black women, who are diagnosed with triple-negative breast cancer at disproportionately higher rates, often at younger ages and with more aggressive rates of the disease.
The approval, announced by Gilead Sciences on June 24, expands how Trodelvy (sacituzumab govitecan-hziy) can be used to treat certain patients. Trodelvy is a targeted cancer therapy that delivers chemotherapy directly to cancer cells. Under the expanded approval, it can now be used on its own for patients who are not good candidates for immunotherapy, or in combination with the immunotherapy drug Keytruda for patients whose tumors test positive for the PD-L1 protein using an FDA-approved test. This gives doctors greater flexibility to tailor treatment based on a patient’s health and the characteristics of their cancer.
What Is Metastatic Triple-Negative Breast Cancer (mTNBC)?
Triple-negative breast cancer (TNBC) is one of the most difficult forms of breast cancer to treat because the cancer cells lack estrogen receptors, progesterone receptors, and excess HER2 protein, the three targets that many standard breast cancer therapies rely on, according to BreastCancer.Org.
RELATED CONTENT: New Study Finds Breast Cancer On The Rise — More Women Under 50 Are Being Diagnosed
When TNBC becomes metastatic, it means the cancer has spread beyond the breast to other parts of the body, including the bones, lungs, liver, or brain. Because hormone therapies and HER2-targeted drugs are ineffective against TNBC, patients have historically had fewer treatment options, and the disease is often considered more aggressive due to its tendency to grow and spread more quickly.
Now, researchers believe Trodelvy could help change that outlook.
The post FDA Approves Trodelvy — A Breakthrough Treatment For One Of The Deadliest Breast Cancers appeared first on MadameNoire.
